Better Imaging for Bone Biopsies
Study Overview
A recent clinical trial found that [18F]FDG PET/CT is more effective than CT for locating biopsy sites in patients with suspected bone metastases. This study involved 273 patients treated between January 2020 and March 2021.
Key Findings
- Higher Accuracy: [18F]FDG PET/CT showed an accuracy of 97.08% compared to 90.44% for CT.
- Better Sensitivity: Sensitivity was 98.76% for [18F]FDG PET/CT, while CT had 92.22%.
- Lower Second Biopsy Rate: Only 2.19% of patients needed a second biopsy with [18F]FDG PET/CT, compared to 5.15% with CT.
- Faster Diagnosis: The average diagnostic time was shorter for [18F]FDG PET/CT (18.33 days) versus CT (21.28 days).
- Cost-Effective: The cost for [18F]FDG PET/CT was 11,428.35 yuan, while CT was 13,287.52 yuan, making PET/CT the more economical choice.
Conclusion
[18F]FDG PET/CT is not only more effective but also more cost-efficient than CT for determining biopsy sites in suspected bone metastases.
Clinical Trials Matter
Clinical trials play a crucial role in developing safe and effective treatments. To make these benefits accessible in everyday medical practice, our AI-driven platform, DocSym, integrates ICD-11 standards, clinical protocols, and research into a single resource for clinicians.
Streamlining Healthcare Operations
In today’s healthcare landscape, efficiency is key. Our mobile apps help with scheduling, treatment monitoring, and telemedicine, simplifying patient care and enhancing digital services.
Enhancing Patient Outcomes
By leveraging AI, clinics can improve workflows, boost patient outcomes, and reduce reliance on paper processes. Discover more about our solutions at aidevmd.com.
